News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Dimensional Fund Advisors LP increased its holdings in Personalis, Inc. (PSNL) by 8.4% in the first quarter, now owning 1.07 million shares valued at approximately $6.8 million. Despite this, insiders have sold a significant amount of stock, and the company has a consensus "Hold" …
Personalis (PSNL) recently reported Q2 2026 results with increased sales but wider losses, leading to a reassessment of its stock by investors. Despite strong recent share price performance, the stock is currently trading slightly above analyst targets, with a narrative fair value suggesting it …
Tempus AI is acquiring Personalis in an all-stock deal valued at $1.5 billion, which positions Tempus AI strategically in the high-growth MRD oncology market. Despite the long-term strategic benefits, Tempus AI's stock experienced a dip following the announcement due to market concerns over valuation, …
Personalis, Inc. (NASDAQ:PSNL) has received an average "Hold" rating from nine analysts, with a 12-month average price target of $14.25. Recent insider selling by executives, totaling over $5.6 million in shares, has been noted. The company's latest quarterly earnings showed mixed results, with revenue …
Personalis, Inc. (PSNL) saw its stock rise by 6.1% after reporting a 30% increase in Q2 revenue to US$22.36 million year-over-year, although net losses deepened to US$31.68 million. Despite flat sales for the first half of 2026, the company reaffirmed its full-year revenue guidance …
Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing its clinical use for minimal residual disease detection in Great Britain. This regulatory approval enables pharmaceutical companies to use the platform in multi-national clinical trials, standardizing detection and potentially accelerating drug …
Personalis, Inc. (PSNL) shows promising growth in the Diagnostics & Research industry, highlighted by a 30% revenue surge driven by its advanced cancer genomic tests. Despite financial challenges like negative EPS and free cash flow deficits, analyst sentiment remains cautiously optimistic, with potential upside …
This article compiles recent news and updates for Personalis Inc (PSNL), primarily focusing on its Q2 2026 financial results, which reported a loss but topped revenue estimates, and the significant acquisition by Tempus AI for $1.5 billion. Several reports also highlight ongoing legal inquiries …
Personalis (PSNL) stock maintains a premium valuation despite reporting deepening losses in Q2 2026, with revenue at US$22.36 million and a net loss of US$31.68 million. While the company has achieved milestones like Medicare coverage for its MRD platform and regulatory wins in the …
Personalis, a cancer genomics testing company, reported a wider loss in Q2 2026 despite increased revenue, driven by higher operating expenses. The company announced it has entered into a merger agreement to be acquired by Tempus AI, Inc. in a cash-stock deal. The merger …
Personalis, Inc. reported strong financial results for the second quarter of 2026, with revenue growing 30% year-over-year to $22.4 million and clinical test volume surging 199%. Key achievements include securing Medicare coverage for its NeXT Personal® test for immunotherapy monitoring and neoadjuvant breast cancer …
Personalis, Inc. (PSNL) announced its Q2 revenue of $22.4 million, significantly exceeding FactSet's estimated $16.7 million. The company, which specializes in advanced cancer genomic tests and analytics, focuses on supporting personalized cancer vaccines and immunotherapies. This earnings beat follows recent news including Tempus AI's …
Personalis, Inc. reported a 30% increase in Q2 2026 revenue to $22.4 million, driven by a 199% surge in clinical test volume and strong pharma testing services. Despite the revenue growth, the company posted a net loss of $31.7 million. Following a merger agreement …
The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (Nasdaq: PSNL) to Tempus AI, Inc. for $16.25 per share. The investigation comes after Tempus shares fell post-announcement, leading to a decrease in Personalis's …
Tempus AI (TEM) reported a profitable Q2 2026, swinging from a net loss to a net income of US$5.64 million, with revenue of US$382.49 million, and subsequently raised its full-year 2026 revenue outlook. The company also announced the acquisition of Personalis, enhancing its oncology …
Personalis Inc is projected to report a loss of 26 cents per share, according to this earnings preview. The article, sourced from Reuters, provides an outlook on the company's upcoming financial performance.
Tempus AI is set to report its second-quarter results, facing investor scrutiny following its $1.5 billion acquisition of Personalis Inc. This deal aims to expand Tempus's cancer-monitoring capabilities, but analysts are divided on its strategic rationale and potential impact on Tempus's path to profitability. …
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We …
BlackRock, Inc. has reported a 5.9% beneficial ownership stake in Personalis, Inc. (PSNL) common stock as of June 30, 2026. This ownership, totaling 6,169,729 shares, grants BlackRock sole voting power over 6,051,493 shares and sole dispositive power over all 6,169,729 shares, as detailed in …
Personalis Inc (PSNL) has a relatively healthy financial standing and high growth potential, with its valuation considered fairly valued in the biotechnology industry. Multiple analysts have rated it as a Buy, projecting an upward trend in the medium term despite recent weak market performance. …
Brodsky & Smith is investigating several companies—Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), and Distribution Solutions Group, Inc. (Nasdaq – DSGR)—regarding potential breaches of fiduciary duties by their boards of directors. These investigations concern whether …
This article provides a valuation analysis of Personalis Inc (PSNL), noting its current valuation score of 6.10, which ranks 357 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -11.76, while also indicating that relevant …
Tempus AI (NASDAQ: TEM) has announced its acquisition of Personalis (NASDAQ: PSNL), a molecular residual disease (MRD) specialist, for approximately $1.5 billion. This primarily all-stock deal aims to integrate Personalis's liquid biopsy technology into Tempus's AI-driven precision medicine platform, enhancing its offerings from diagnosis …
Personalis (PSNL) has agreed to be acquired by Tempus AI. Following this announcement, Monteverde & Associates initiated an investigation into the fairness of the transaction terms for Personalis shareholders. The stock has seen significant short-term gains, but a mixed longer-term performance, making the acquisition …
Tempus AI is set to acquire molecular diagnostics company Personalis for approximately $1.5 billion, enhancing Tempus's capabilities in molecular residual disease (MRD) testing and cancer monitoring. This acquisition follows a 2023 partnership and aims to integrate Personalis's MRD technology with Tempus's AI precision oncology …
Monteverde & Associates PC, a class action firm, has launched an investigation into the sale of Personalis, Inc. (NASDAQ: PSNL) to Tempus AI, Inc. The firm is examining whether the proposed transaction, which offers Personalis shareholders $16.25 per share, is a fair deal. Shareholders …
Tempus AI is set to acquire Personalis, Inc., with both companies detailing the associated merger risks and upcoming SEC filings in a Form 425 document. Key risks include failure to secure stockholder or regulatory approvals, potential litigation, integration challenges, and a termination clause allowing …
Personalis (PSNL) achieved commercial success through increased clinical adoption, Medicare reimbursement expansion, and a strong MRD platform. However, the all-stock acquisition by Tempus AI at a 6% premium transforms PSNL from an independent growth story to one dependent on Tempus's share price. Despite operational …
Search by ticker symbol or company name and select a result to open its chart.